H. Stewart Parker Net Worth & Insider Trades

H. Stewart Parker - Director, Sangamo Therapeutics, Inc

As of June 5, 2023

What is H. Stewart Parker's Net Worth?

The current estimated net worth of Sangamo Therapeutics, Inc's Director, H. Stewart Parker, is estimated to be about $135.68K . H. Stewart Parker owns about 48,700 units of Sangamo Therapeutics, Inc common stock. In the last 5 years at Sangamo Therapeutics, Inc, H. Stewart Parker has sold an estimated value of $0 worth.

What is H. Stewart Parker's Past Insider Trading?

H. Stewart Parker's largest purchase order was 2,000 units , worth over $18K on November 15, 2018. In total, H. Stewart Parker has made about 8 transactions over 5 years of their time at Sangamo Therapeutics, Inc. H. Stewart Parker usually trades in June and March, with the busiest year in 2020 and 2022. The most recent transaction was a purchase order of 5,000 units , worth over $18K on June 3, 2022.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

H. Stewart Parker

Date Range: All Time
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...

InsideArbitrage

Our partner InsideArbitrage provides a full suite of tools and analysis that allows you to find opportunities from the hundreds of insiders transactions filed by company insiders each week. The service includes the popular Insider Weekends articles that highlight the top 5 insider purchases and sales each week as well as detailed analysis of one company each week. The service also includes several custom screens such as the Double Dipper that includes a list of companies that are buying back their shares while their insiders are independently buying stock on the open market for their own portfolios.

What was H. Stewart Parker's Salary in 2020?

As Director of Sangamo Therapeutics, Inc, H. Stewart Parker has a total base salary of $318,283 . H. Stewart Parker received compensation valued at about $1,433,976 in 2020 after becoming Director. The vast majority of their compensation came in the form of stock awards of $374,000 , option awards of $485,221 , other compensation of $256,472 .

Sangamo Therapeutics, Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Alexander D. Macrae 2020 $681,797 - $1,147,500 $1,488,746 $511,348 $5,639 $3,835,030
Alexander D. Macrae 2019 $661,939 - $571,148 $2,274,230 $436,880 $42,358 $3,986,555
Alexander D. Macrae 2018 $636,480 - $631,575 $2,410,657 $420,077 $5,639 $4,104,428
Sung H. Lee 2020 $438,262 - $340,000 $443,316 $215,000 $5,639 $1,442,217
Sung H. Lee 2019 $72,500 $200,000 $452,813 $1,757,679 $47,415 $273 $2,530,680
Gary H. Loeb 2020 $406,000 - $340,000 $441,110 $200,564 $5,639 $1,393,313
Gary H. Loeb 2019 $166,667 - - $1,788,475 $87,200 $683 $2,043,025
D. Mark McClung 2020 $276,667 $150,000 $916,000 $1,187,220 $136,245 $5,093 $2,671,225
R. Andrew Ramelmeier 2020 $416,000 $50,000 $374,000 $485,221 $203,840 $5,639 $1,534,700
R. Andrew Ramelmeier 2019 $382,965 - $112,875 $449,453 $153,608 $5,639 $1,104,540
Stéphane Boissel 2020 $318,283 - $374,000 $485,221 - $256,472 $1,433,976
Stéphane Boissel 2019 $483,600 - $158,025 $629,234 $212,784 $1,639 $1,485,282
Stéphane Boissel 2018 $120,390 $100,000 - $2,052,792 - $316,884 $2,590,066
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1001233/000162828021006458/sgmo_proxyx2021xdefxvs.htm

What are Sangamo Therapeutics, Inc's Past Insider Trades?

Sangamo Therapeutics, Inc's most recent insider trade came on August 31, 2022 by Biogen Inc and Biogen Ma Inc who sold 500,000 units worth $2.66M . In the last 19 years, insiders at Sangamo Therapeutics, Inc have sold an estimated value of $143.79M and bought an estimated value of $70.12M worth of shares. Insider trading is most common in June, with the busiest year in 2014. The most active traders at the company are Edward Lanphier II, Director,  Philip Gregory, SVP Research & CSO,  and Ward Henry Wolff, Exec VP & CFO .

SANGAMO THERAPEUTICS, INC Insider Trades

Date Range: All Time
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...